Inogen (NASDAQ:INGN) Stock

INOGEN INC

Inogen

Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. Internationally, It sells its products through distributors large gas companies, and home oxygen providers. It generates the majority of its revenue in the United States.

Inogen Inc

WIIM

INGN

Inogen shares are trading lower after the company reported Q1 financial results and issued Q2 sales guidance below estimates. Also, Stifel maintained a Hold rating on the stock and lowered its price target from $10 to $7.

Stifel analyst Mathew Blackman maintains Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) with a Hold and lowers the price target from $10 to $7.

News

Price Target

Analyst Ratings

Stifel Maintains Hold on Inogen, Lowers Price Target to $7

Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) sees Q2 sales of $89.000 million-$91.000 million vs $92.73 million analyst estimate.

Guidance

Inogen Sees Q2 Sales $89.000M-$91.000M vs $92.73M Est

Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) affirms FY2025 sales outlook from $352.00 million-$355.00 million to $352.00 million-$355.00 million vs $352.81 million estimate.

Inogen Affirms FY2025 Sales Guidance of $352.00M-$355.00M vs $352.81M Est

Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.50) by 78 percent. This is a 75.56 percent increase over losses of $(0.45) per share from the same period last year. The company reported quarterly sales of $82.28 million which beat the analyst consensus estimate of $79.55 million by 3.43 percent. This is a 5.45 percent increase over sales of $78.03 million the same period last year.

Earnings

Earnings Beats

Inogen Q1 Adj. EPS $(0.11) Beats $(0.50) Estimate, Sales $82.28M Beat $79.55M Estimate

ACAD

ACDC

ACRE

ACVA

ADMA

ADNT

ADTN

AIRG

ALNT

ALTG

ALTO

ALVO

AMPH

AMPL

AMRK

AMRN

AOSL

APLS

ARIS

ARMN

ASLE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AVDX

AXON

AXTA

AZTA

BAND

BBDO

BBGI

BBSI

BGSF

Brighthouse Financial, Inc. - Common Stock

BLBD

BLMN

BLZE

BMBL

BRKR

BROS

BTMD

BXSL

BYND

CAPL

CCSI

CDLX

CENT

CENTA

CENX

CEVA

CIVI

CMTG

CNDT

COHR

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRNC

CRNT

CSGS

CSTE

CTVA

CVNA

CYRX

Earnings Scheduled For May 7, 2025

Needham analyst Mike Matson reiterates Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) from Hold to Hold.

Reiteration

Needham Reiterates Hold on Inogento Hold

Medical Technology company Inogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) reported a fourth-quarter adjusted EPS loss of 24 cents, compared to a loss of 83 cents a year ago, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus loss of 61 cents</a>.
The company reported sales of $80.1 million, beating the consensus of $73.9 million.
Total revenue in the fourth quarter of 2024 increased 5.5% year over year, primarily driven by higher demand and new customers in international and domestic business-to-business sales, partially offset by lower direct-to-consumer sales and lower rental revenue as a result of the company's initiatives to <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43956475/inogen-announces-fourth-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">enhance overall profitability</a>.
"2024 was a stellar year for Inogen. With our new leadership team in place, we returned the company to growth, achieved significant milestones, and made meaningful steps towards profitability," said Kevin Smith, president and CEO. "With our leading portfolio of innovative respiratory care products, the pending introduction of Simeox in the U.S. and our recently announced collaboration with Yuwell, we believe we are well positioned to drive future growth, profitability, and sustained success."
Adjusted EBITDA loss was $3.6 million in the fourth quarter of 2024 compared to $17.3 million a year ago.
Guidance: Inogen expects first quarter 2025 sales of $79 million-$81 million versus consensus of $78.1 million.
The company expects fiscal year 2025 sales of $352 million-$355 million versus a consensus of $344.61 million.
Analyst Reaction:
<ul>
<li>JP Morgan writes, &#8220;With initial guidance for 1Q25 also starting off a step above the Street, we view today as another step forward towards what we hope to be fully normalized trends in 2H25 ahead of more meaningful contribution from strategic initiatives in 2026+.&#8221;</li>
<li>Analyst Robbie Marcus notes that while the company has a strong product in the underdeveloped POC market, its short-term outlook is uncertain. Supply challenges remain unresolved, and another sales team restructuring adds to the uncertainty.</li>
<li>JP Morgan maintains the Underweight rating with a <a href="https://www.benzinga.com/quote/INGN/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $10</a>.</li>
<li>Needham analyst Mike Matson reiterates Inogen with a Hold rating.</li>
<li>William Blair says, &#8220;Despite the softer DTC and rental segments, Inogen continues to see strength in its B2B segments in the U.S. and internationally. In our view, strength in this segment is durable and, although stepping down in 2025 off tougher comps, should continue to drive performance.&#8221;</li>
<li>Analyst Margaret Kaczor Andrew says the company is on a clear path to profitability and will soon benefit from recent management-driven changes in strategy, culture, and organization.</li>
</ul>
Price Action: INGN stock reached as high as $11.85 during the premarket trading before falling 9.45% to $8.60 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/25/02/43972083/amazons-25-billion-robotics-push-targets-cost-savings-ai-growth-and-temu-competition-report" target="_blank" rel="noreferrer noopener">Amazon&#8217;s $25 Billion Robotics Push Targets Cost Savings, AI Growth And Temu Competition: Report</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Health Care

Movers

Trading Ideas

General

What's Going On With MedTech Focused Inogen Stock On Wednesday?

Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) sees FY2025 sales of $352.000 million-$355.000 million vs $344.61 million analyst estimate.

Inogen Sees FY2025 Sales $352.000M-$355.000M vs $344.61M Est

Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) sees Q1 sales of $79.000 million-$81.000 million vs $78.08 million analyst estimate.

Inogen Sees Q1 Sales $79.000M-$81.000M vs $78.08M Est

Inogen shares are trading higher after the company reported better-than-expected Q4 financial results.

Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.61) by 60.66 percent. This is a 71.08 percent increase over losses of $(0.83) per share from the same period last year. The company reported quarterly sales of $80.08 million which beat the analyst consensus estimate of $73.91 million by 8.35 percent. This is a 5.51 percent increase over sales of $75.90 million the same period last year.

Inogen Q4 Adj $(0.24) Beats $(0.61) Estimate, Sales $80.08M Beat $73.91M Estimate

AHCO

ALLT

ARQT

AXGN

BASE

BGFV

BTDR

BWIN

CART

CAVA

CBLL

CCCS

CECO

CGBD

CHRD

CIFR

CPNG

CPSS

DAWN

DNUT

DOCN

DRVN

ELAN

EXLS

FIHL

FLYW

FSLR

FULC

GPOR

HRMY

HSIC

HURN

HYLN

IART

ICCC

IGIC

IMOS

INTU

INVX

IPAR

ITRI

IVAC

JACK

JAZZ

KEYS

KNSA

LCID

LGIH

LIVN

LMND

LXFR

MASI

MATX

MFIC

MIDD

MMSI

MPLN

MRVI

NOVT

NXRT

Earnings Scheduled For February 25, 2025

The strategic collaboration is expected to broaden Inogen's product portfolio through distribution of certain respiratory products in the United States and select other territories, expand and enhance Inogen's innovation pipeline through R&amp;D collaboration, and accelerate the entry of Inogen's brand into the Chinese market. In addition, Yuwell, through its affiliate, has agreed to invest approximately $27.2 million in Inogen, representing a 9.9% common equity interest, further cementing the collaboration and bolstering Inogen's balance sheet.

Reported Sunday, Inogen And Yuwell Forge Strategic Collaboration To Broaden Global Reach And Develop Next-Generation Respiratory Solutions

<h3>Gainers</h3>
<ul>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) stock increased by 43.9% to $14.92 during Thursday's pre-market session. The market value of their outstanding shares is at $45.3 million. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) shares moved upwards by 42.88% to $0.19. The market value of their outstanding shares is at $1.3 million. </li>
<li>Oncology Institute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) shares increased by 13.54% to $0.8. The market value of their outstanding shares is at $60.3 million. </li>
<li>Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) shares moved upwards by 12.74% to $12.21. The company's market cap stands at $290.8 million. </li>
<li>IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) shares rose 12.53% to $0.29. The market value of their outstanding shares is at $21.0 million. </li>
<li>Vigil Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>) shares moved upwards by 12.31% to $2.28. The company's market cap stands at $93.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ALX Oncology Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) shares fell 16.7% to $1.5 during Thursday's pre-market session. The company's market cap stands at $79.1 million. </li>
<li>Jupiter Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JUNS#NASDAQ">JUNS</a>) shares decreased by 14.53% to $3.06. The market value of their outstanding shares is at $101.2 million. </li>
<li>Channel Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#AMEX">CHRO</a>) shares fell 11.48% to $2.39. The company's market cap stands at $14.4 million. </li>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) shares fell 10.0% to $1.8. The company's market cap stands at $5.4 million. </li>
<li>Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) shares decreased by 8.98% to $0.4. The company's market cap stands at $7.0 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock fell 8.91% to $0.75. The market value of their outstanding shares is at $2.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALXO

CHRO

HEPA

HSDT

INAB

JUNS

SONN

VIGL

XCUR

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Inogen Estimates Preliminary FY24 Total Revenue Of $334.5M - $335.5M (Est $329.615M), Exceeding Prior Guidance Range Of $329M - $331M

Press Releases

Sight Sciences Appoints MK Raheja as Executive Vice President, Research and Development and Brenton Taylor as Executive Vice President, Operations

Inogen Announces Third Quarter 2024 Financial Results

Inogen Receives FDA 510(k) Clearance for SIMEOX 200 Airway Clearance Device

Inogen Announces Preliminary Fourth Quarter and Full Year 2024 Revenue

Inogen Expands Product Portfolio, Global Reach and Innovation Pipeline Through Strategic Collaboration With Yuwell

Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West

Comments

Inogen

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL